A vs ABNB Stock Comparison

Scores Breakdown

Metric	A	ABNB
📈 Growth	26/30	14/30
💰 Profitability	17/20	18/20
🏦 Financial Health	15/20	16/20
💵 Valuation	16/20	13/20
⚠️ Risk (lower is better)	5/10	7/10
Overall Score	79/100	64/100

Side-by-Side Summaries

A Analysis	ABNB Analysis
📈 Growth & Financial Trajectory Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility. 💰 Margins & Cash Flow Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity. 🛡️ Balance Sheet & Liquidity Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure. ⚠️ Key Drivers & Risks Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption. Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.	📈 Growth & Financial Trajectory Over 8 quarters, Revenue declined modestly from $3.732B in Q3 2024 to $3.608B in Q2 2026, while Net Income rose from $461M to $816M, with a peak of $1.374B in Q3 2025 before a mid-year dip. This shows profitability resilience amid revenue variability, driven by episodic operating leverage. Overall, the growth signal is modest on revenue but improving on bottom-line momentum into Q2 2026. 💰 Margins & Cash Flow Gross Margin has remained high, generally in the mid to high 70s up to mid 80s percent across quarters. Operating Margin has been volatile, ranging from near-breakeven to about 39–61% in select quarters, recently around 21% in Q2 2026 as scale expands. Net cash flow from operating activities has been positive in most periods (e.g., ~$1.79B in Q1 2025; $1.27B in Q2 2026), with notable quarterly outflows in Q4 2025 (-$3.73B), reflecting seasonality and financing/investing activity. 🛡️ Balance Sheet & Liquidity Current assets consistently in the low 20s of billions vs current liabilities in the mid to high teens, yielding a healthy current ratio (~1.4–1.6). Long-term debt sits around $2.48B, with equity around $7.6–8.7B across periods, indicating modest leverage and solid equity base. Liabilities plus equity align with asset bases, suggesting liquidity resilience. ⚠️ Key Drivers & Risks Drivers: Travel demand resurgence; network effects and marketplace scale. Risks: Travel cyclicality and regulatory/commercial risk; valuation sensitivity to quarterly volatility and travel headlines.

A Analysis

ABNB Analysis

📈 Growth & Financial Trajectory

Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility.

💰 Margins & Cash Flow

Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity.

🛡️ Balance Sheet & Liquidity

Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure.

⚠️ Key Drivers & Risks

Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption.
Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.

📈 Growth & Financial Trajectory

Over 8 quarters, Revenue declined modestly from $3.732B in Q3 2024 to $3.608B in Q2 2026, while Net Income rose from $461M to $816M, with a peak of $1.374B in Q3 2025 before a mid-year dip. This shows profitability resilience amid revenue variability, driven by episodic operating leverage. Overall, the growth signal is modest on revenue but improving on bottom-line momentum into Q2 2026.

💰 Margins & Cash Flow

Gross Margin has remained high, generally in the mid to high 70s up to mid 80s percent across quarters.
Operating Margin has been volatile, ranging from near-breakeven to about 39–61% in select quarters, recently around 21% in Q2 2026 as scale expands.
Net cash flow from operating activities has been positive in most periods (e.g., ~$1.79B in Q1 2025; $1.27B in Q2 2026), with notable quarterly outflows in Q4 2025 (-$3.73B), reflecting seasonality and financing/investing activity.

🛡️ Balance Sheet & Liquidity

Current assets consistently in the low 20s of billions vs current liabilities in the mid to high teens, yielding a healthy current ratio (~1.4–1.6).
Long-term debt sits around $2.48B, with equity around $7.6–8.7B across periods, indicating modest leverage and solid equity base. Liabilities plus equity align with asset bases, suggesting liquidity resilience.

⚠️ Key Drivers & Risks

Drivers: Travel demand resurgence; network effects and marketplace scale.
Risks: Travel cyclicality and regulatory/commercial risk; valuation sensitivity to quarterly volatility and travel headlines.

Similar Companies

AMAT Score: 79 AME Score: 78 ANET Score: 85 GOOGL Score: 80 TMO Score: 75 WAT Score: 74

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"